Imipenem/cilastatin therapy in the management of infections in the outpatient setting

Infectious Diseases in Clinical Practice

Volumn 5, Issue 8, 1996, Pages 498-501

  Marsh, Peter K ^a  

^a Infectious Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN; IMIPENEM;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GOOD CLINICAL PRACTICE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; OUTPATIENT CARE; RASH; UNITED STATES; VOMITING;

EID: 0030450348     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199611000-00009     Document Type: Article

References (5)

1. Norrby SR, Alestig K, Bjornegard B, et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother 1983;23:300-7.
2. Kropp H, Sundelof JG, Kahan JS, et al. MK9787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother 1980;17: 993-1000.
3. Neu HC, Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its β-lactamase stability. Antimicrob Agents Chemother 1982;21:180-7.
4. Neu HC. Chemical perspectives on imipenem. J Antimicrob Chemother 1983;12(Suppl D):149-53.
5. Fish DN, Piscitelli S, Danziger L. Development of resistance during antimicrobial therapy: review of antibiotic classes and patient characteristics in 173 studies. Pharrnacotherapy 1995;15:279-91.